An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease (SHIELD-4)

January 25, 2018 updated by: GlaxoSmithKline

A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease

This is a multi-centre, randomised, double-blind, active treatment, parallel group induction study in subjects with moderately-to-severely active Crohn's disease. Subjects will receive one of two doses (500 milligrams once daily, 500 milligrams twice daily) of GSK1605786A for 12 weeks. The primary objective of the study is to induce clinical response (Crohn's Disease Activity Index [CDAI] decrease from baseline of at least 100 points) and/or remission (CDAI score less than 150) with GSK1605786A at Week 12 in subjects with active Crohn's disease to qualify subjects for enrolment into a 52 week maintenance study (CCX114157). Secondary objectives will include assessment of the safety and evaluation of the efficacy in induction of clinical response or remission. Safety will be assessed by recording of adverse events and assessment of changes in clinical laboratory parameters, vital signs and electrocardiogram. Population pharmacokinetics will evaluate the two doses of GSK1605786A. Health outcomes assessments will include changes in Inflammatory Bowel Disease Questionnaire, SF-36, EQ-5D, and Work Productivity and Activity Impairment-Crohn's Disease.

Study Overview

Status

Terminated

Conditions

Crohn's Disease

Intervention / Treatment

Detailed Description

This is a multi-centre, double-blind, randomised, active treatment, parallel group study designed to induce clinical response and/or clinical remission with two oral doses of GSK1605786A (500 milligrams once daily, 500 milligrams twice daily) over a 12-week treatment period in subjects with moderately-to-severely active Crohn's disease. The primary objective of this study is to qualify subjects for enrolment into a follow up 52 week maintenance study CCX114157. Subjects who achieve induction of clinical response (CDAI decrease from baseline of at least 100 points) or remission (CDAI score less than 150) at Week 12 following treatment with GSK1605786A will be eligible for enrolment into the maintenance study CCX114157. Secondary objectives will include assessment of the safety and evaluation of the efficacy in induction of clinical response or remission.

The study is planned to randomise approximately 900 subjects (450 subjects per group) with active Crohn's disease who have been diagnosed for at least 4 months, with documented history of disease in the small and/or large intestine, and characterised by a CDAI score between 220 to 450 (inclusive). Subjects will be required to have evidence of current active inflammation by elevated C-reactive protein (greater than the upper limit of normal of the highly sensitive C-reactive protein test) OR an elevated level of faecal calprotectin. Subjects will be allowed to participate in the study while continuing on stable doses of agents typically used to treat Crohn's disease. Inclusion of subjects who received prior treatment with an anti-tumor necrosis factor agent and discontinued due to loss or lack of efficacy will be limited to approximately 50 percent of the study population. Following a 3-week screening period, subjects will be randomised at baseline to receive blinded treatment with one of two doses of GSK1605786A (500 milligrams once daily or twice daily) for 12 weeks. All subjects meeting the definition of responder (CDAI decrease from baseline of at least 100 points) or who are in remission (CDAI score less than 150 points) at Week 12 will be eligible for randomisation into an ongoing maintenance study (CCX114157). Subjects who do not meet the definition of responder or who are not in remission at Week 12 will not be eligible to participate in study CCX114157.

For subjects who complete the study the minimum duration of participation is 15 weeks and the maximum duration is 19 weeks.

Study Type

Interventional

Enrollment (Actual)

255

Phase

Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Australia
- New South Wales
  - Bankstown, New South Wales, Australia, 2200
    - GSK Investigational Site
- South Australia
  - Adelaide, South Australia, Australia, 5000
    - GSK Investigational Site
- Victoria
  - Box Hill, Victoria, Australia, 3128
    - GSK Investigational Site
  - Fitzroy, Victoria, Australia, 3065
    - GSK Investigational Site
  - Prahran, Victoria, Australia, 3181
    - GSK Investigational Site
- Western Australia
  - Fremantle, Western Australia, Australia, 6160
    - GSK Investigational Site
Austria
- - Hall in Tirol, Austria, 6060
    - GSK Investigational Site
  - Linz, Austria, A-4021
    - GSK Investigational Site
  - Oberpullendorf, Austria, 7350
    - GSK Investigational Site
  - St.Veit/Glan, Austria, 9300
    - GSK Investigational Site
  - Wien, Austria, 1030
    - GSK Investigational Site
  - Wien, Austria, 1050
    - GSK Investigational Site
  - Wien, Austria, 1090
    - GSK Investigational Site
Belgium
- - Bonheiden, Belgium, 2820
    - GSK Investigational Site
  - Edegem, Belgium, 2650
    - GSK Investigational Site
  - Gent, Belgium, 9000
    - GSK Investigational Site
  - Kortrijk, Belgium, 8500
    - GSK Investigational Site
  - Leuven, Belgium, 3000
    - GSK Investigational Site
  - Roeselare, Belgium, 8800
    - GSK Investigational Site
Bulgaria
- - Plovdiv, Bulgaria, 4002
    - GSK Investigational Site
  - Sofia, Bulgaria, 1431
    - GSK Investigational Site
  - Sofia, Bulgaria, 1407
    - GSK Investigational Site
  - Sofia, Bulgaria, 1527
    - GSK Investigational Site
  - Varna, Bulgaria, 9010
    - GSK Investigational Site
Canada
- Ontario
  - Kingston, Ontario, Canada, K7L 5G2
    - GSK Investigational Site
  - London, Ontario, Canada, N6A 5A5
    - GSK Investigational Site
  - London, Ontario, Canada, N6A 5W9
    - GSK Investigational Site
Chile
- - Vina del Mar, Chile, 2520012
    - GSK Investigational Site
Czechia
- - Hradec Králové, Czechia, 500 12
    - GSK Investigational Site
  - Olomouc, Czechia, 77520
    - GSK Investigational Site
  - Praha 4, Czechia, 140 59
    - GSK Investigational Site
  - Praha 9, Czechia, 190 61
    - GSK Investigational Site
  - Teplice, Czechia, 415 29
    - GSK Investigational Site
  - Usti nad Orlici, Czechia, 562 18
    - GSK Investigational Site
Denmark
- - Aalborg, Denmark, 9000
    - GSK Investigational Site
  - Aarhus, Denmark, 8000
    - GSK Investigational Site
  - Herlev, Denmark, 2730
    - GSK Investigational Site
  - Koebenhavn NV, Denmark, 2400
    - GSK Investigational Site
Estonia
- - Tallinn, Estonia, 10617
    - GSK Investigational Site
  - Tallinn, Estonia, EE-10138
    - GSK Investigational Site
  - Tartu, Estonia, 51014
    - GSK Investigational Site
France
- - Clichy cedex, France, 92118
    - GSK Investigational Site
  - Lille cedex, France, 59037
    - GSK Investigational Site
  - Paris cedex 10, France, 75475
    - GSK Investigational Site
  - Saint-Priest en Jarez, France, 42270
    - GSK Investigational Site
Germany
- - Berlin, Germany, 10117
    - GSK Investigational Site
  - Hamburg, Germany, 20148
    - GSK Investigational Site
- Baden-Wuerttemberg
  - Heidelberg, Baden-Wuerttemberg, Germany, 69120
    - GSK Investigational Site
  - Mannheim, Baden-Wuerttemberg, Germany, 68167
    - GSK Investigational Site
  - Ulm, Baden-Wuerttemberg, Germany, 89081
    - GSK Investigational Site
- Bayern
  - Weiden, Bayern, Germany, 92637
    - GSK Investigational Site
- Hessen
  - Frankfurt am Main, Hessen, Germany, 60590
    - GSK Investigational Site
- Mecklenburg-Vorpommern
  - Rostock, Mecklenburg-Vorpommern, Germany, 18057
    - GSK Investigational Site
- Niedersachsen
  - Brinkum/Stuhr, Niedersachsen, Germany, 28816
    - GSK Investigational Site
  - Hannover, Niedersachsen, Germany, 30625
    - GSK Investigational Site
- Nordrhein-Westfalen
  - Koeln, Nordrhein-Westfalen, Germany, 50937
    - GSK Investigational Site
  - Minden, Nordrhein-Westfalen, Germany, 32423
    - GSK Investigational Site
- Sachsen
  - Dresden, Sachsen, Germany, 01307
    - GSK Investigational Site
- Sachsen-Anhalt
  - Halle, Sachsen-Anhalt, Germany, 06120
    - GSK Investigational Site
  - Magdeburg, Sachsen-Anhalt, Germany, 39120
    - GSK Investigational Site
- Thueringen
  - Jena, Thueringen, Germany, 07747
    - GSK Investigational Site
Greece
- - Athens, Greece, 10676
    - GSK Investigational Site
  - Athens, Greece, 11522
    - GSK Investigational Site
  - Athens, Greece, 18454
    - GSK Investigational Site
  - Heraklion, Crete, Greece, 71110
    - GSK Investigational Site
  - Ioannina, Greece, 45110
    - GSK Investigational Site
Hong Kong
- - Hong Kong, Hong Kong
    - GSK Investigational Site
  - Shatin, New Territories, Hong Kong
    - GSK Investigational Site
Hungary
- - Bekescsaba, Hungary, 5600
    - GSK Investigational Site
  - Budapest, Hungary, 1062
    - GSK Investigational Site
  - Budapest, Hungary, 1083
    - GSK Investigational Site
  - Budapest, Hungary, 1136
    - GSK Investigational Site
  - Budapest, Hungary, 1088
    - GSK Investigational Site
  - Debrecen, Hungary, 4025
    - GSK Investigational Site
  - Mosonmagyaróvár, Hungary, 9200
    - GSK Investigational Site
  - Szekszárd, Hungary, 7100
    - GSK Investigational Site
  - Vác, Hungary, 2600
    - GSK Investigational Site
Israel
- - Afula, Israel, 18101
    - GSK Investigational Site
  - Beer Sheva, Israel, 84101
    - GSK Investigational Site
  - Haifa, Israel, 31096
    - GSK Investigational Site
  - Holon, Israel, 58100
    - GSK Investigational Site
  - Jerusalem, Israel, 91031
    - GSK Investigational Site
  - Jerusalem, Israel, 91120
    - GSK Investigational Site
  - Kfar Saba, Israel, 44281
    - GSK Investigational Site
  - Petah Tikva, Israel, 49100
    - GSK Investigational Site
  - Ramat-Gan, Israel, 52621
    - GSK Investigational Site
  - Tel Aviv, Israel, 64239
    - GSK Investigational Site
  - Zerifin, Israel, 70300
    - GSK Investigational Site
Italy
- - Genova, Italy, 16132
    - GSK Investigational Site
Japan
- - Aichi, Japan, 460-0012
    - GSK Investigational Site
  - Aichi, Japan, 441-8570
    - GSK Investigational Site
  - Aichi, Japan, 470-1219
    - GSK Investigational Site
  - Fukuoka, Japan, 818-8502
    - GSK Investigational Site
  - Fukuoka, Japan, 802-0077
    - GSK Investigational Site
  - Fukuoka, Japan, 830-0011
    - GSK Investigational Site
  - Hiroshima, Japan, 720-8520
    - GSK Investigational Site
  - Hokkaido, Japan, 065-0033
    - GSK Investigational Site
  - Hyogo, Japan, 663-8501
    - GSK Investigational Site
  - Kagoshima, Japan, 892-0846
    - GSK Investigational Site
  - Kanagawa, Japan, 220-0045
    - GSK Investigational Site
  - Kanagawa, Japan, 247-0056
    - GSK Investigational Site
  - Osaka, Japan, 530-0011
    - GSK Investigational Site
  - Shizuoka, Japan, 430-0846
    - GSK Investigational Site
  - Tokyo, Japan, 169-0073
    - GSK Investigational Site
  - Wakayama, Japan, 641-8510
    - GSK Investigational Site
Korea, Republic of
- - Daegu, Korea, Republic of, 705-717
    - GSK Investigational Site
  - Pusan, Korea, Republic of, 602-739
    - GSK Investigational Site
  - Seoul, Korea, Republic of, 120-752
    - GSK Investigational Site
  - Seoul, Korea, Republic of, 130702
    - GSK Investigational Site
  - Seoul, Korea, Republic of, 138-736
    - GSK Investigational Site
  - Seoul, Korea, Republic of, 135-230
    - GSK Investigational Site
  - Wonju, Korea, Republic of, 220701
    - GSK Investigational Site
Netherlands
- - Amsterdam, Netherlands, 1105 AZ
    - GSK Investigational Site
  - Amsterdam, Netherlands, 1081 HV
    - GSK Investigational Site
  - Amsterdam, Netherlands, 1091 AC
    - GSK Investigational Site
  - EDE, Netherlands, 6716 RP
    - GSK Investigational Site
  - Eindhoven, Netherlands, 5623 EJ
    - GSK Investigational Site
  - Rotterdam, Netherlands, 3083 AN
    - GSK Investigational Site
New Zealand
- - Canterbury, New Zealand, 8011
    - GSK Investigational Site
  - Dunedin, New Zealand, 9054
    - GSK Investigational Site
  - Hamilton, New Zealand, 3204
    - GSK Investigational Site
  - Lower Hutt, New Zealand, 6007
    - GSK Investigational Site
  - Otahuhu, New Zealand, 1640
    - GSK Investigational Site
  - Takapuna, Auckland, New Zealand, 1309
    - GSK Investigational Site
  - Tauranga., New Zealand, 3143
    - GSK Investigational Site
Poland
- - Bydgoszcz, Poland, 85-168
    - GSK Investigational Site
  - Bydgoszcz, Poland, 85-681
    - GSK Investigational Site
  - Lublin, Poland, 20-607
    - GSK Investigational Site
  - Sopot, Poland, 81-756
    - GSK Investigational Site
  - Wroclaw, Poland, 53-333
    - GSK Investigational Site
Portugal
- - Lisboa, Portugal, 1649-035
    - GSK Investigational Site
  - Lisboa, Portugal, 1769-001
    - GSK Investigational Site
  - Porto, Portugal, 4099-001
    - GSK Investigational Site
  - Viseu, Portugal, 3504-509
    - GSK Investigational Site
Russian Federation
- - Irkutsk, Russian Federation, 664079
    - GSK Investigational Site
  - Kazan, Russian Federation, 420064
    - GSK Investigational Site
  - Lipetsk, Russian Federation, 398055
    - GSK Investigational Site
  - Moscow, Russian Federation, 129110
    - GSK Investigational Site
  - Nizhniy Novgorod, Russian Federation, 603126
    - GSK Investigational Site
  - Rostov-on-Don, Russian Federation, 344091
    - GSK Investigational Site
  - Samara, Russian Federation, 443011
    - GSK Investigational Site
  - St. Petersburg, Russian Federation, 196247
    - GSK Investigational Site
  - St.Petersburg, Russian Federation, 197110
    - GSK Investigational Site
  - Tomsk, Russian Federation, 634063
    - GSK Investigational Site
Slovakia
- - Bratislava, Slovakia, 831 04
    - GSK Investigational Site
  - Bratislava, Slovakia, 851 01
    - GSK Investigational Site
  - Bratislava, Slovakia, 851 07
    - GSK Investigational Site
  - Nitra, Slovakia, 949 01
    - GSK Investigational Site
  - Nove Mesto nad Vahom, Slovakia, 915 01
    - GSK Investigational Site
  - Presov, Slovakia, 080 01
    - GSK Investigational Site
  - Trnava, Slovakia, 917 02
    - GSK Investigational Site
Spain
- - Badalona, Spain, 08916
    - GSK Investigational Site
  - Elche, Spain, 03293
    - GSK Investigational Site
  - Fuenlabrada (Madrid), Spain, 28942
    - GSK Investigational Site
  - Galdakao/Vizcaya, Spain, 48960
    - GSK Investigational Site
  - Madrid, Spain, 28006
    - GSK Investigational Site
  - Madrid, Spain, 28007
    - GSK Investigational Site
  - Madrid, Spain, 28040
    - GSK Investigational Site
  - Madrid, Spain, 28046
    - GSK Investigational Site
  - Marbella, Spain, 29600
    - GSK Investigational Site
  - Sabadell (Barcelona), Spain, 08208
    - GSK Investigational Site
  - Santander, Spain, 39008
    - GSK Investigational Site
Switzerland
- - Bern, Switzerland, 3004
    - GSK Investigational Site
  - Zürich, Switzerland, 8091
    - GSK Investigational Site
Taiwan
- - Taichung, Taiwan, 40705
    - GSK Investigational Site
  - Taipei, Taiwan, 100
    - GSK Investigational Site
  - Taipei, Taiwan, 104
    - GSK Investigational Site
  - Taoyuan, Taiwan, 333
    - GSK Investigational Site
Turkey
- - Ankara, Turkey, 06100
    - GSK Investigational Site
Ukraine
- - Chernivtsi, Ukraine, 58005
    - GSK Investigational Site
  - Dnipropetrovsk, Ukraine, 49044
    - GSK Investigational Site
  - Donetsk, Ukraine, 83017
    - GSK Investigational Site
  - Donetsk, Ukraine, 83099
    - GSK Investigational Site
  - Kharkiv, Ukraine, 61037
    - GSK Investigational Site
  - Kyiv, Ukraine
    - GSK Investigational Site
  - Odesa, Ukraine, 65117
    - GSK Investigational Site
  - Simferopol, Ukraine, 95017
    - GSK Investigational Site
  - Vinnytsya, Ukraine, 21029
    - GSK Investigational Site
United Kingdom
- - Birmingham, United Kingdom, B9 5SS
    - GSK Investigational Site
  - Dundee, United Kingdom, DD1 9SY
    - GSK Investigational Site
  - Edinburgh, United Kingdom, EH4 2XU
    - GSK Investigational Site
  - London, United Kingdom, E1 2AT
    - GSK Investigational Site
  - Manchester, United Kingdom, M13 9WL
    - GSK Investigational Site
  - Newcastle Upon Tyne, United Kingdom, NE1 4LP
    - GSK Investigational Site
  - Oxford, United Kingdom, OX3 9DU
    - GSK Investigational Site
- Lanarkshire
  - Glasgow, Lanarkshire, United Kingdom, G4 0SF
    - GSK Investigational Site
- Middlesex
  - Harrow, Middlesex, United Kingdom, HA1 3UJ
    - GSK Investigational Site
United States
- Arizona
  - Little Rock, Arizona, United States, 72205
    - GSK Investigational Site
  - Tucson, Arizona, United States, 85712
    - GSK Investigational Site
- California
  - La Jolla, California, United States, 92037
    - GSK Investigational Site
- Colorado
  - Aurora, Colorado, United States, 80045
    - GSK Investigational Site
  - Denver, Colorado, United States, 80222
    - GSK Investigational Site
  - Littleton, Colorado, United States, 80120
    - GSK Investigational Site
- Connecticut
  - Hamden, Connecticut, United States, 06518
    - GSK Investigational Site
  - New Haven, Connecticut, United States, 06510
    - GSK Investigational Site
- District of Columbia
  - Washington, District of Columbia, United States, 20007
    - GSK Investigational Site
- Florida
  - Jacksonville, Florida, United States, 32256-6004
    - GSK Investigational Site
  - Port Orange, Florida, United States, 32127
    - GSK Investigational Site
- Georgia
  - Suwanee, Georgia, United States, 30024
    - GSK Investigational Site
- Illinois
  - Chicago, Illinois, United States, 60637
    - GSK Investigational Site
- Maryland
  - Chevy Chase, Maryland, United States, 20815
    - GSK Investigational Site
  - Towson, Maryland, United States, 21204
    - GSK Investigational Site
  - Towson, Maryland, United States, 21286
    - GSK Investigational Site
- Massachusetts
  - Boston, Massachusetts, United States, 02114
    - GSK Investigational Site
- Michigan
  - Chesterfield, Michigan, United States, 48047
    - GSK Investigational Site
- Minnesota
  - Rochester, Minnesota, United States, 55905
    - GSK Investigational Site
- Missouri
  - Lee's Summit, Missouri, United States, 64064
    - GSK Investigational Site
  - Mexico, Missouri, United States, 65265-3726
    - GSK Investigational Site
- New York
  - Brooklyn, New York, United States, 11206
    - GSK Investigational Site
  - Lake Success, New York, United States, 11042
    - GSK Investigational Site
  - Stony Brook, New York, United States, 11794
    - GSK Investigational Site
- North Carolina
  - Chapel Hill, North Carolina, United States, 27599
    - GSK Investigational Site
  - Charlotte, North Carolina, United States, 28207
    - GSK Investigational Site
  - Charlotte, North Carolina, United States, 28209
    - GSK Investigational Site
- Ohio
  - Columbus, Ohio, United States, 43215
    - GSK Investigational Site
- Oklahoma
  - Tulsa, Oklahoma, United States, 74135
    - GSK Investigational Site
- Oregon
  - Portland, Oregon, United States, 97225
    - GSK Investigational Site
- Pennsylvania
  - Pittsburgh, Pennsylvania, United States, 15212
    - GSK Investigational Site
- Tennessee
  - Nashville, Tennessee, United States, 37232
    - GSK Investigational Site
- Texas
  - Austin, Texas, United States, 78745
    - GSK Investigational Site
- Utah
  - Ogden, Utah, United States, 84405
    - GSK Investigational Site
- Virginia
  - Christiansburg, Virginia, United States, 24073
    - GSK Investigational Site
  - Danville, Virginia, United States, 24541
    - GSK Investigational Site
  - Norfolk, Virginia, United States, 23502
    - GSK Investigational Site
  - Richmond, Virginia, United States, 23249
    - GSK Investigational Site
- Wisconsin
  - Madison, Wisconsin, United States, 53792
    - GSK Investigational Site
  - Milwaukee, Wisconsin, United States, 53226
    - GSK Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Genders Eligible for Study

All

Description

Inclusion Criteria:

Male or female subjects aged 18 years or older
Written informed consent prior to any of the screening procedures including discontinuation of prohibited medications
Diagnosis of Crohn's disease for more than 4 months with small bowel and/or colonic involvement
Current evidence of moderately-to-severely active disease defined by a baseline Crohn's Disease Activity Index (CDAI) score of 220 to 450, inclusive
Confirmation of active disease by elevated CRP (greater than or equal to the upper limit of normal for the highly sensitive C-reactive protein test) or elevated levels of faecal calprotectin
History of inadequate response and/or intolerance or adverse event leading to discontinuation of at least one of the following treatments for Crohn's disease: corticosteroids or immunosuppressants
Stable doses of permitted concomitant medications or having previously received, but are not currently receiving, medications for Crohn's disease
Demonstrated ability to comply with Crohn's disease symptom recording using the interactive voice response system
Female subjects of child-bearing potential are eligible if not pregnant or nursing and committed to use of contraceptive methods with a failure rate of less than 1 percent per year

Exclusion Criteria:

Known coeliac disease, those who follow a gluten-free diet to manage symptoms of suspected coeliac disease and subjects with a positive screening test for coeliac disease (elevated anti-tissue transglutaminase antibodies)
Diagnosis of ulcerative or indeterminate colitis
Enterocutaneous, abdominal or pelvic fistulae with abscesses, or fistulae likely to require surgery during the course of the study period
Bowel surgery, other than appendectomy, within 12 weeks prior to screening and/or has planned surgery or deemed likely to need surgery for Crohn's disease during the study period
Extensive colonic resection, subtotal or total colectomy
Presence of ileostomies, colostomies or rectal pouches
Fixed symptomatic stenoses of small bowel or colon
History of more than 3 small bowel resections or diagnosis of short bowel syndrome
Chronic use of narcotics for chronic pain defined as daily use of one or more doses of narcotic containing medicaitons
Use of prohibited medications, including enteral feeding or elemental diet, within their specified timeframes and throughout the study. Prohibited medications include the following:
1. Biologic use: Use of any TNF inhibitor (such as infliximab, adalimumab or certolizumab) or natalizumab within 10 weeks prior to Randomisation
2. Corticosteroid use: Use of parenteral glucocorticoids within 4 weeks prior to Screening
3. Immunospressant use: Use of cyclosporine, tacrolimus, sirolimus or mycophenolate mofetil within 4 weeks prior to Screening
4. Intravenous antibiotic use: Use of intravenous antibiotics for Crohn's disease within 4 weeks prior to Screening
5. Enteral feeding: Use of tube or enteral feeding, elemental diet within 2 weeks prior to Screening
6. Rectal Treatment: Use of 5-aminosalicylates or corticosteroid enemas or suppositories within 2 weeks prior to Screening
7. Leukocytapheresis or granulocytapheresis within 2 weeks prior to Screening
8. Paracetamol or acetaminophen greater than 2 grams per day
9. Opioid analgesics for worsening Crohn's disease pain are prohibited when used on a regular daily basis for more than 3 days
10. Digoxin or related cardiac glycosides: Use within 7 days prior to Screening
11. Any previous participation in a clinical study of GSK1605786A (formerly ChemoCentryx compound CCX282-B)
Positive immunoassay for Clostridium difficile
Known HIV infection
Known varicella, herpes zoster, or other severe viral infection within 6 weeks of screening
Immunization with a live vaccine within 4 weeks of Screening and throughout the study with the exception of the influenza vaccine
Positive hepatitis B surface antigen or hepatitis B core antibody test or positive Hepatitis C test result at Screening
Active or latent tuberculosis infection determined by results of QuantiFERON TB Gold test
Current sepsis or infections requiring intravenous antibiotic therapy for more than 2 weeks
Previous infections characterised by opportunistic pathogens, and/or dissemination suggestive of clinically significant immunocompromise
Evidence of hepatic dysfunction, viral hepatitis, or abnormalities in liver function test results
Corrected QT interval of ECG (electrocardiogram) greater than or equal to 450 milliseconds
Congenital or acquired immunodeficiency or has evidence of immunocompromise manifested by current opportunistic infection
Current evidence of, or has been treated for a malignancy within the past five years (other than localised basal cell, squamous cell skin cancer, cervical dysplasia, or any cancer in situ that has been resected)
History of evidence of adenomatous colonic polyps that have not been removed.
History of evidence of colonic mucosal dysplasia
If female, is pregnant, has a positive pregnancy test or is breast-feeding
Concurrent illness or disability that may affect the interpretation of clinical data, or otherwise contraindicates participation in this clinical study (such as an unstable cardiovascular, autoimmune, renal, hepatic, pulmonary, endocrine, metabolic, gastrointestinal, haematologic, or neurological condition or mental impairment)
Medical history of sensitivity to any of the components of GSK1605786A (microcrystalline cellulose, crospovidone, sodium stearyl fumarate).
Use of any investigational product within 30 days prior to screening

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Interventional Model: Parallel Assignment
Masking: Quadruple

Number of Arms

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: GSK1605786A, 500 milligrams, once daily 500 milligrams once daily, orally administered for 12 weeks	Drug: GSK1605786A 500 milligrams once daily, orally administered for 12 weeks Drug: GSK1605786A 500 milligrams twice daily, orally adminstered for 12 weeks
Experimental: GSK1605786A, 500 milligrams twice daily 500 milligrams twice daily, orally administered for 12 weeks	Drug: GSK1605786A 500 milligrams once daily, orally administered for 12 weeks Drug: GSK1605786A 500 milligrams twice daily, orally adminstered for 12 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants Achieving Clinical Response at Week 12 Time Frame: At Week 12	Clinical response, defined as decrease in Crohn's disease activity index (CDAI) score, from Baseline value of >=100 points. Baseline defined as Week 0. CDAI is scoring system measuring disease severity with scores of >=220 to <=450 describing moderately-to-severely active population(higher score indicated severe disease). Contains 8 questions related to disease symptoms; soft tools in 7 days (weightage (Wt)as 2; abdominal pain over 7 days Wt= 5; general well being Wt= 7;Crohn's disease symptoms Wt=20; antidiarrhoeal medication used Wt=30; abdominal mass Wt=10; Anemia Wt=10; standard weight with Wt=1.Total CDAI score algorithmically derived from participants-reported above Crohn's disease symptoms and investigator recorded assessments, calculated by Interactive Voice Response System. Missing efficacy data, imputed using "no effect" imputation where missing was no response or no change in response (were non-responders). If baseline CDAI, < 100,participant was considered non-responder.	At Week 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants Achieving Clinical Remission at Week 8, Week 12 and at Both Week 8 and Week 12 Time Frame: Week 8 and Week 12	Clinical remission is defined as a CDAI score of <150 points. CDAI is scoring system measuring disease severity with scores of >=220 to <=450 describing moderately-to-severely active population(higher score indicated severe disease). Contains 8 questions related to disease symptoms; soft tools in 7 days (weightage (Wt)as 2; abdominal pain over 7 days Wt= 5; general well being Wt= 7;Crohn's disease symptoms Wt=20; antidiarrhoeal medication used Wt=30; abdominal mass Wt=10; Anemia Wt=10; standard weight with Wt=1.Total CDAI score algorithmically derived from participants-reported above Crohn's disease symptoms and investigator recorded assessments, calculated by Interactive Voice Response System. Missing efficacy data, imputed using "no effect" imputation where missing was no response or no change in response (were non-responders). If the Baseline value was <150, the participant was not considered to have achieved remission.	Week 8 and Week 12
Percentage of Participants With a Clinical Response at Week 8 and at Both Week 8 and Week 12 Time Frame: Both Week 8 and Week 12	Clinical response, defined as decrease in Crohn's disease activity index (CDAI) score, from Baseline value of >=100 points. Baseline defined as Week 0. CDAI is scoring system measuring disease severity with scores of >=220 to <=450 describing moderately-to-severely active population(higher score indicated severe disease). Contains 8 questions related to disease symptoms; soft tools in 7 days (weightage (Wt)as 2; abdominal pain over 7 days Wt= 5; general well being Wt= 7;Crohn's disease symptoms Wt=20; antidiarrhoeal medication used Wt=30; abdominal mass Wt=10; Anemia Wt=10; standard weight with Wt=1.Total CDAI score algorithmically derived from participants-reported above Crohn's disease symptoms and investigator recorded assessments, calculated by Interactive Voice Response System. Missing efficacy data, imputed using "no effect" imputation where missing was no response or no change in response (were non-responders). If baseline CDAI, < 100,participant was considered non-responder.	Both Week 8 and Week 12
Change From Baseline in C-reactive Protein Concentration at Weeks 4, 8, and 12 Time Frame: Baseline (Screening) and Weeks 4, 8, and Week 12	Blood samples were planned to be collected for the measurement of C-reactive protein at Baseline (Screening) and at Weeks 4, 8, and 12. Baseline is defined as the measurement at Screening (Day -21 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time points (Week 4, week 8 and week 12) minus the value at Baseline respectively. The study was terminated prematurely due to absence of favorable benefit-to-risk profile of GSK1605786A, and thus data for this outcome measure was not collected.	Baseline (Screening) and Weeks 4, 8, and Week 12
Change From Baseline in Faecal Calprotectin at Week 12 Time Frame: Baseline (Screening) and Week 12	Stool samples were planned to be collected for the measurement faecal calprotectin level at Baseline (Screening) and Week 12. Baseline is defined as the measurement at Screening (Day -21 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline. The study was terminated prematurely due to absence of favorable benefit-to-risk profile of GSK1605786A, and thus data for this outcome measure was not collected.	Baseline (Screening) and Week 12
Pharmacokinetics (PK) of GSK1605786A Time Frame: Baseline (Screening) and Week 12	The PK analyses was planned to perform to characterize the PK of the study drug GSK1605786A, in the participant population. PK is defined as the concentration of drug in a participant's blood at certain time points after the drug was taken by mouth. PK sampling was to be conducted at week 2, 4, 6 ,8, 10 and week 12 (pre-dose, post-dose 0.5 hour (hr) to 2 hr, 3 to 6 hr, and 6 to 28 hr post-dose. The study was terminated prematurely due to absence of favorable benefit-to-risk profile of GSK1605786A, and thus the data for this outcome measure was not collected.	Baseline (Screening) and Week 12
Pharmacogenetic Analyses Time Frame: Post randomization any time during early two weeks	Sample for the pharmacogenetic analyses was collected during any one of the Treatment Phase visit (Week 2, 4, 6, or 8 ). The pharmacogenetic analyses was planned to perform to investigate the relationship between the genetic markers with the safety and efficacy response to GSK1605786A. These pharmacogenetic analyses was not conducted following the early termination of the study. The study was terminated prematurely due to absence of favorable benefit-to-risk profile of GSK1605786A, and thus data was not collected for this outcome measure.	Post randomization any time during early two weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

GlaxoSmithKline

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 11, 2011

Primary Completion (Actual)

October 17, 2013

Study Completion (Actual)

October 17, 2013

Study Registration Dates

First Submitted

February 16, 2012

First Submitted That Met QC Criteria

February 16, 2012

First Posted (Estimate)

February 22, 2012

Study Record Updates

Last Update Posted (Actual)

January 29, 2018

Last Update Submitted That Met QC Criteria

January 25, 2018

Last Verified

January 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

114643

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Crohn's Disease

ProgenaBiome

Recruiting

A Pilot Study to Explore the Role of Gut Flora in Crohn's Disease

Crohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's Esophagitis | Crohn's | Crohn Disease of Ileum | Crohn Ileitis | Crohn's Disease Relapse | Crohns Disease Aggravated | Crohn Disease in Remission | Crohn's Disease of Pylorus

United States
Massachusetts General Hospital
American College of Gastroenterology

Not yet recruiting

Personalized Risk Estimation for Crohn's Disease (PRE-CD): Implementation and Feasibility

Inflammatory Bowel Diseases | Crohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's Esophagitis

United States
Agomab Spain S.L.

Recruiting

STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease

Fibrostenotic Crohn's Disease

United States, Italy, Poland, Spain, Denmark, Austria, Canada, Germany
Sheba Medical Center

Completed

The CURE - CD Trial

CD - Crohn's Disease

Israel
AbbVie

Active, not recruiting

A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease

Crohn's Disease (CD)

United States, Belgium, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, New Zealand, Norway, Poland, Romania, Slovakia, Spain, United Kingdom
Richard Burt, MD

Terminated

Hematopoietic Stem Cell Support in Patients With Severe Crohn's Disease

CROHN'S DISEASE

United States
AbbVie

Active, not recruiting

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD) (SEQUENCE)

Crohn's Disease (CD)

United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Romania, Russian Federation, Slo... and more
University Hospital, Lille
Ministry of Health, France

Terminated

Effect of Fluconazole on the Levels of ASCA After Surgical Resection for Crohn's Disease. (AscaMC)

Crohn's Disease Aggravated

France
University of Michigan

Recruiting

A Pilot Study Examining Low Sulfur Diet as Treatment for Persistent Symptoms in Quiescent Crohn's Disease

Crohn's Disease in Remission

United States
Washington University School of Medicine
American College of Gastroenterology

Recruiting

Response Assessment in SB CD

Small Bowel Crohn's Disease

United States

Clinical Trials on GSK1605786A

GlaxoSmithKline

Terminated

Open-Label Extension Study of GSK1605786A (SHIELD-3)

Crohn's Disease

United States, France, Spain, Bulgaria, Poland, Ukraine, South Africa, Sweden, Israel, Korea, Republic of, Belgium, Australia, Austria, Canada, Chile, Czechia, Denmark, Estonia, Germany, Hong Kong, Hungary, Italy, Japan, New Zealand, Po... and more
GlaxoSmithKline

Completed

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease (SHIELD-1)

Crohn's Disease

United States, France, Netherlands, Spain, Germany, Poland, Belgium, South Africa, Sweden, Israel, Korea, Republic of, Australia, Austria, Canada, Czechia, Denmark, Hungary, Italy, Japan, New Zealand, Norway, Slovakia, United Kingdom
GlaxoSmithKline

Terminated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease (SHIELD-2)

Crohn's Disease

United States, France, Netherlands, Spain, Bulgaria, Poland, Ukraine, South Africa, Sweden, Israel, Korea, Republic of, Belgium, Australia, Austria, Canada, Chile, Czechia, Denmark, Estonia, Germany, Hong Kong, Hungary, Italy, Japan, New... and more

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease (SHIELD-4)

A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease

Study Overview

Status

Conditions

Intervention / Treatment

Detailed Description

Study Type

Enrollment (Actual)

Phase

Contacts and Locations

Study Locations

Participation Criteria

Eligibility Criteria

Ages Eligible for Study

Accepts Healthy Volunteers

Genders Eligible for Study

Description

Study Plan

How is the study designed?

Design Details

Number of Arms

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure

Measure Description

Time Frame

Secondary Outcome Measures

Outcome Measure

Measure Description

Time Frame

Collaborators and Investigators

Sponsor

Study record dates

Study Major Dates

Study Start (Actual)

Primary Completion (Actual)

Study Completion (Actual)

Study Registration Dates

First Submitted

First Submitted That Met QC Criteria

First Posted (Estimate)

Study Record Updates

Last Update Posted (Actual)

Last Update Submitted That Met QC Criteria

Last Verified

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Studies a U.S. FDA-regulated device product

Clinical Trials on Crohn's Disease

Clinical Trials on GSK1605786A

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations